Alterity Therapeutics (ATHE) Shares Outstanding (2009 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Shares Outstanding (Entity) of $159.9 million for Q2 2025, up 75.31% year-over-year from $91.2 million in Q2 2024, and up 75.31% quarter-over-quarter from $91.2 million in Q2 2024.
Alterity Therapeutics (ATHE) Shares Outstanding (2009 - 2025) Analysis & Trends
Alterity Therapeutics' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $159.9 million for Q2 2025.
- In Q2 2025, Shares Outstanding (Entity) rose 75.31% year-over-year to $159.9 million; the TTM figure through Jun 2025 stood at $159.9 million (up 75.31% YoY), while the FY2025 annual figure was $159.9 million, up 75.31% from the prior year.
- Shares Outstanding (Entity) for Q2 2025 stood at $159.9 million, up from $91.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $159.9 million in Q2 2025, with the low at $4.2 million in Q2 2021.
- The 5-year median for Shares Outstanding (Entity) is $33.4 million (2022), against an average of $54.7 million.
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) jumped 41.79% in 2022, then soared 909.08% in 2023.
- Alterity Therapeutics' Shares Outstanding (Entity) stood at $6.0 million in 2021, then rose by 0.04% to $6.0 million in 2022, then jumped by 909.08% to $60.7 million in 2023, then soared by 50.29% to $91.2 million in 2024, then soared by 75.31% to $159.9 million in 2025.
- Business Quant data shows ATHE's Shares Outstanding (Entity) at $159.9 million in Q2 2025, $91.2 million in Q2 2024, and $60.7 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 445.06 Mn |
| 10 | Alterity Therapeutics | 48.83 Mn | 16.53 Mn | - | 10.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.40 Bn |
| Jun 30, 2025 | 6.40 Bn |
| Dec 31, 2024 | 3.65 Bn |
| Jun 30, 2024 | 3.65 Bn |
| Dec 31, 2023 | 2.43 Bn |
| Jun 30, 2023 | 2.43 Bn |
| Dec 31, 2022 | 240.60 Mn |
| Jun 30, 2022 | 240.60 Mn |
| Dec 31, 2021 | 240.51 Mn |
| Jun 30, 2021 | 169.69 Mn |
| Dec 31, 2020 | 132.34 Mn |
| Jun 30, 2020 | 89.49 Mn |
| Dec 31, 2019 | 86.83 Mn |
| Jun 30, 2019 | 61.58 Mn |
| Dec 31, 2018 | 53.39 Mn |
| Jun 30, 2018 | 53.39 Mn |
| Dec 31, 2017 | 53.39 Mn |
| Jun 30, 2017 | 53.39 Mn |
| Dec 31, 2016 | 53.39 Mn |
| Jun 30, 2016 | 53.39 Mn |